<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02434497</url>
  </required_header>
  <id_info>
    <org_study_id>D356NC00001</org_study_id>
    <nct_id>NCT02434497</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia</brief_title>
  <official_title>An Open-Label Long-Term Extension to the Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (Aged 6 to &lt;18 Years) With Homozygous Familial Hypercholesterolemia (HoFH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety of Rosuvastatin in Children and
      Adolescents with Homozygous Familial Hypercholesterolemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a long-term extension (LTE) to the randomized, double-blind, cross-over study of
      rosuvastatin 20 mg once daily (QD) versus placebo QD in children and adolescents (aged from 6
      to &lt;18 years) with homozygous familial hypercholesterolemia (HoFH) (Study D3561C00004).

      The study is designed to assess the long-term safety and tolerability of rosuvastatin 20 mg
      in pediatric patients with HoFH.

      In this study all patients will receive rosuvastatin 20 mg QD. Investigators will also be
      permitted to titrate the dose of rosuvastatin from 20 to 40 mg per day if they feel it is
      warranted to more aggressively treat patients' elevated LDL-C levels. This up-titration will
      not be permitted in Asian patients. Pharmacokinetic data of the trough plasma exposure of
      rosuvastatin will also be assessed for the pediatric patients with HoFH taking a daily dose
      of rosuvastatin 40 mg.

      The primary outcome measures to be assessed include 1) Adverse events, including:

        -  The frequency and severity of adverse events,

        -  Rate of discontinuations due to adverse events,

        -  Abnormal serum and urine laboratory values, electrocardiograms (ECGs), physical
           examinations, and vital signs; and 2) Assessments of growth.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2015</start_date>
  <completion_date type="Actual">November 17, 2016</completion_date>
  <primary_completion_date type="Actual">November 17, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants Who Experianced Adverse Events and Serious Adverse Events</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Number of Participants Who Had Adverse Events, Discontinuations Due to Adverse Events</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Basophils/Leukocytes (%) &gt;Upper Limite of Normal (ULN)</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Growth, Height</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormalitites in Sexual Maturation</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Growth, Height SD-score (or Z-score)</measure>
    <time_frame>96 weeks</time_frame>
    <description>Height z-score is a dimensionless quantity derived by subtracting the population mean from the individual raw score, and then deviding the difference by the pouulation SD of the reference population. This indicates how many SDs and observation is above or below the general population mean.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Growth, Weight</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Alanine Aminotransferase (U/L) &gt;ULN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Albumin (g/dL) &gt;ULN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Aspartate Aminotransferase (U/L) &gt;ULN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) &lt;LLN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) &gt;ULN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB Concentration (g/dL) &lt;LLN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB (pg) &lt;LLN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) &lt;LLN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) &gt;ULN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) &lt;LLN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) &gt;ULN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hematocrit (%) &lt;LLN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hemoglobin (g/dL) &lt;LLN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Leukocytes &gt;ULN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) &lt;LLN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) &gt;ULN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Monocytes/Leukocytes (%) &gt;ULN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Platelets (10^9/L) &gt;ULN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Blood Urea Nitrogen (mg/dL) &lt;LLN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Chloride (mmol/L) &gt;ULN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Creatine Kinase (U/L) &gt;ULN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Glucose (mg/dL) &gt;ULN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lactate Dehydrogenase (U/L) &lt;LLN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Phosphate (mg/dL) &gt;ULN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Protein (g/dL) &gt;ULN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Sodium (mmol/L) &lt;LLN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Urate (mg/dL) &gt;ULN</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Ketones</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Occult Blood</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Protein</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal ECG, Abnormalities</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Physical Exams, Cardiovascular</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Physical Exams, General Appearance</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Physical Exams, Head and Neck</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Physical Exams, Musculoskeletal/Extremities</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Physical Exams, Skin</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability in Terms of Abnormal Vital Signs</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in LDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</measure>
    <time_frame>Up to 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</measure>
    <time_frame>Up to 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Cholesterol (TC) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</measure>
    <time_frame>Up to 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Triglycerides (TG) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</measure>
    <time_frame>Up to 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Non-HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</measure>
    <time_frame>Up to 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in LDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</measure>
    <time_frame>Up to 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in TC/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</measure>
    <time_frame>Up to 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Non-HDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</measure>
    <time_frame>Up to 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in ApoB From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</measure>
    <time_frame>Up to 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</measure>
    <time_frame>Up to 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in ApoB/ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</measure>
    <time_frame>Up to 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile in Terms of Trough Concentrations in Pediatric HoFH Taking a Daily Dose of Rosuvastatin 40mg</measure>
    <time_frame>Up to 22 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia (HoFH)</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One treatment period for all patients (&lt;1 year and 10 months), with the possibility to up-titrate dose to 40 mg of rosuvastatin for non-Asian patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20mg</intervention_name>
    <description>Active drug 1 or 2 tablets will be taken taken orally, QD, either in the morning or in the evening</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Prior to any study related procedures being performed, provision of written informed
             consent from a parent/both parents or guardian and statement of assent from the child
             or adolescent (if required by Institutional Review Board [IRB] or Independent Ethics
             Committee [IEC] according to local regulations and guidelines). Study D3561C00004
             participants who have had their 18th birthday (adults) will be required to provide
             written informed consent. Communication should take place between the Investigator,
             patient/guardian and child/adolescent to confirm understanding and required compliance
             with the requirements of the study.

          2. Male and female children and adolescents who were aged 6 to &lt;18 years at the onset of
             Study D3561C00004 (even if they had their 18th birthday during that study) with:

               -  Documentation of genetic testing confirming 2 mutated alleles of the LDL receptor
                  gene locus; and/or

               -  Documented untreated LDL C &gt;500 mg/dL (12.9 mmol/L) and TG &lt;400 mg/dL (4.5
                  mmol/L) and at least 1 of the following criteria:

                    -  Tendinous and/or cutaneous xanthoma prior to 10 years of age; or

                    -  Documentation of HeFH in both parents by:

               -  genetic and/or

               -  clinical criteria

          3. Negative pregnancy test (b human chorionic gonadotropin analysis) prior to baseline in
             females of child bearing potential:

               -  Female patients of child bearing potential must adhere to a pregnancy prevention
                  method (abstinence, chemical, or mechanical) during the study and 3 months
                  following the last dose;

               -  Male patients should refrain from fathering a child (including sperm donation)
                  during the study and up to 3 months following the last dose; and

          4. Were taking study drug at the end of Study D3561C00004 and are willing to follow all
             study procedures including adherence to dietary guidelines, study visits, fasting
             blood draws, and compliance with study treatment regimens.

        Exclusion Criteria:

          1. History of statin inducted myopathy or serious hypersensitivity reaction to other HMG
             CoA reductase inhibitors (statins), including rosuvastatin, at Visit 1 of Study
             D3561C00004.

          2. Fasting serum glucose of &gt;9.99 mmol/L (180 mg/dL) or glycosylated hemoglobin &gt;9%
             during Study D3561C00004 or patients with a history of diabetic ketoacidosis within
             the past year.

          3. Uncontrolled hypothyroidism defined as thyroid stimulating hormone &gt;1.5 times the
             upper limit of normal (ULN) at any time during Study D3561C00004.

          4. Evidence of active liver disease or hepatic dysfunction (except a confirmed diagnosis
             of Gilbert's disease) as defined as non-transient elevations of ALT or AST elevations
             ≥3 times the ULN or non-transient total bilirubin ≥2 times the ULN during the Study
             D3561C00004.

          5. Definite or suspected personal history or family history of clinically significant
             adverse drug reactions (ADRs), or hypersensitivity to drugs with a similar chemical
             structure to rosuvastatin as well as other statins.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels (Woluwé-St-Lambert)</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 7K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halfa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kubang Kerian</city>
        <zip>16150</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei City</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Israel</country>
    <country>Malaysia</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2015</study_first_submitted>
  <study_first_submitted_qc>April 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <results_first_submitted>April 21, 2017</results_first_submitted>
  <results_first_submitted_qc>February 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 27, 2018</results_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LDL-C</keyword>
  <keyword>HoFH</keyword>
  <keyword>Hyperlipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The nine (9) patients recruited were all participants in the D3561C00004 HYDRA study (NCT02226198) four came from Sequence A and five from Sequence B</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall</title>
          <description>All patients</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>All patients</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.6" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants Who Experianced Adverse Events and Serious Adverse Events</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Full analysis set, comprised of patient who received at least one dose of study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Who Experianced Adverse Events and Serious Adverse Events</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Number of Participants Who Had Adverse Events, Discontinuations Due to Adverse Events</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Full analysis set, comprised of patient who received at least one dose of study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Number of Participants Who Had Adverse Events, Discontinuations Due to Adverse Events</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Basophils/Leukocytes (%) &gt;Upper Limite of Normal (ULN)</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Basophils/Leukocytes (%) &gt;Upper Limite of Normal (ULN)</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="0" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="0" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="0" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="0" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Growth, Height</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Growth, Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.5" spread="23.57"/>
                    <measurement group_id="O2" value="136.8" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.5" spread="23.57"/>
                    <measurement group_id="O2" value="136.8" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.0" spread="23.90"/>
                    <measurement group_id="O2" value="137.6" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.3" spread="23.56"/>
                    <measurement group_id="O2" value="138.0" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.8" spread="24.02"/>
                    <measurement group_id="O2" value="139.2" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.0" spread="24.15"/>
                    <measurement group_id="O2" value="140.6" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.8" spread="24.25"/>
                    <measurement group_id="O2" value="142.2" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.0" spread="19.47"/>
                    <measurement group_id="O2" value="144.0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.0" spread="20.22"/>
                    <measurement group_id="O2" value="145.0" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.7" spread="20.43"/>
                    <measurement group_id="O2" value="148.3" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.0" spread="25.46"/>
                    <measurement group_id="O2" value="138.0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormalitites in Sexual Maturation</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Full analysis set, comprised of patient who received at least one dose of study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormalitites in Sexual Maturation</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Growth, Height SD-score (or Z-score)</title>
        <description>Height z-score is a dimensionless quantity derived by subtracting the population mean from the individual raw score, and then deviding the difference by the pouulation SD of the reference population. This indicates how many SDs and observation is above or below the general population mean.</description>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Growth, Height SD-score (or Z-score)</title>
          <description>Height z-score is a dimensionless quantity derived by subtracting the population mean from the individual raw score, and then deviding the difference by the pouulation SD of the reference population. This indicates how many SDs and observation is above or below the general population mean.</description>
          <units>standard deviations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="2.025"/>
                    <measurement group_id="O2" value="-1.05" spread="1.787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="1.911"/>
                    <measurement group_id="O2" value="-1.05" spread="1.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="1.975"/>
                    <measurement group_id="O2" value="-1.19" spread="1.709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="1.610"/>
                    <measurement group_id="O2" value="-1.14" spread="1.705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="1.730"/>
                    <measurement group_id="O2" value="-0.96" spread="1.670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="1.836"/>
                    <measurement group_id="O2" value="-0.76" spread="1.727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="1.781"/>
                    <measurement group_id="O2" value="-0.72" spread="1.729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="1.757"/>
                    <measurement group_id="O2" value="-1.04" spread="1.604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="1.635"/>
                    <measurement group_id="O2" value="-0.87" spread="1.604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="1.734"/>
                    <measurement group_id="O2" value="-0.33" spread="1.627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="0.436"/>
                    <measurement group_id="O2" value="-0.51" spread="0.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Growth, Weight</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Growth, Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.25" spread="14.719"/>
                    <measurement group_id="O2" value="37.42" spread="16.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.20" spread="16.230"/>
                    <measurement group_id="O2" value="38.02" spread="16.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.93" spread="17.110"/>
                    <measurement group_id="O2" value="38.16" spread="17.501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.85" spread="17.633"/>
                    <measurement group_id="O2" value="38.40" spread="16.688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.15" spread="17.521"/>
                    <measurement group_id="O2" value="39.00" spread="16.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.98" spread="18.293"/>
                    <measurement group_id="O2" value="39.88" spread="15.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.00" spread="17.579"/>
                    <measurement group_id="O2" value="41.16" spread="16.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.47" spread="16.933"/>
                    <measurement group_id="O2" value="41.80" spread="15.656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.43" spread="16.393"/>
                    <measurement group_id="O2" value="42.10" spread="17.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.17" spread="16.737"/>
                    <measurement group_id="O2" value="45.28" spread="19.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.35" spread="16.476"/>
                    <measurement group_id="O2" value="33.55" spread="2.192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Alanine Aminotransferase (U/L) &gt;ULN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Alanine Aminotransferase (U/L) &gt;ULN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="1" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="1" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="1" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="1" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="1" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="1" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Albumin (g/dL) &gt;ULN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Albumin (g/dL) &gt;ULN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="1" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="1" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="0" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="0" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="0" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Aspartate Aminotransferase (U/L) &gt;ULN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Aspartate Aminotransferase (U/L) &gt;ULN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="0" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="0" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="0" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="1" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="0" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) &lt;LLN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) &lt;LLN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="1" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.90"/>
                    <measurement group_id="O2" value="1" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="1" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.02"/>
                    <measurement group_id="O2" value="1" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.15"/>
                    <measurement group_id="O2" value="2" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.25"/>
                    <measurement group_id="O2" value="1" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="19.47"/>
                    <measurement group_id="O2" value="3" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="20.22"/>
                    <measurement group_id="O2" value="1" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="20.43"/>
                    <measurement group_id="O2" value="1" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="1" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) &gt;ULN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) &gt;ULN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="0" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="0" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="0" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="1" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB Concentration (g/dL) &lt;LLN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB Concentration (g/dL) &lt;LLN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="23.57"/>
                    <measurement group_id="O2" value="3" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="2" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="23.90"/>
                    <measurement group_id="O2" value="2" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.56"/>
                    <measurement group_id="O2" value="2" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="24.02"/>
                    <measurement group_id="O2" value="3" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.15"/>
                    <measurement group_id="O2" value="3" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.25"/>
                    <measurement group_id="O2" value="4" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="19.47"/>
                    <measurement group_id="O2" value="4" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="20.22"/>
                    <measurement group_id="O2" value="3" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="20.43"/>
                    <measurement group_id="O2" value="3" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="1" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB (pg) &lt;LLN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB (pg) &lt;LLN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.57"/>
                    <measurement group_id="O2" value="3" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.57"/>
                    <measurement group_id="O2" value="2" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.90"/>
                    <measurement group_id="O2" value="2" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.56"/>
                    <measurement group_id="O2" value="2" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.02"/>
                    <measurement group_id="O2" value="2" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.15"/>
                    <measurement group_id="O2" value="2" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.25"/>
                    <measurement group_id="O2" value="3" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="3" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="3" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="3" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="25.46"/>
                    <measurement group_id="O2" value="1" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) &lt;LLN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) &lt;LLN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.57"/>
                    <measurement group_id="O2" value="2" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.57"/>
                    <measurement group_id="O2" value="2" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.90"/>
                    <measurement group_id="O2" value="2" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.56"/>
                    <measurement group_id="O2" value="2" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.02"/>
                    <measurement group_id="O2" value="2" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.15"/>
                    <measurement group_id="O2" value="2" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.25"/>
                    <measurement group_id="O2" value="2" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="2" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="3" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="3" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="25.46"/>
                    <measurement group_id="O2" value="1" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) &gt;ULN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) &gt;ULN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="0" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="0" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="0" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="0" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) &lt;LLN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) &lt;LLN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="1" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="1" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="1" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="0" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="1" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) &gt;ULN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) &gt;ULN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="1" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="1" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="0" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.02"/>
                    <measurement group_id="O2" value="2" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="2" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="1" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="1" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="2" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="1" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="1" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hematocrit (%) &lt;LLN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hematocrit (%) &lt;LLN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="23.57"/>
                    <measurement group_id="O2" value="2" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="23.57"/>
                    <measurement group_id="O2" value="3" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.90"/>
                    <measurement group_id="O2" value="2" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.56"/>
                    <measurement group_id="O2" value="3" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="1" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.15"/>
                    <measurement group_id="O2" value="1" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="2" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="2" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="1" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="1" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hemoglobin (g/dL) &lt;LLN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hemoglobin (g/dL) &lt;LLN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="23.57"/>
                    <measurement group_id="O2" value="3" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="23.57"/>
                    <measurement group_id="O2" value="3" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.90"/>
                    <measurement group_id="O2" value="3" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.56"/>
                    <measurement group_id="O2" value="3" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="2" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.15"/>
                    <measurement group_id="O2" value="3" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.25"/>
                    <measurement group_id="O2" value="3" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="3" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="3" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="3" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="1" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Leukocytes &gt;ULN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Leukocytes &gt;ULN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="0" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="0" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="1" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="0" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) &lt;LLN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) &lt;LLN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="0" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="0" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="1" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="0" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) &gt;ULN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) &gt;ULN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="1" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="1" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="1" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="1" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="1" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="1" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="1" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="1" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="0" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Monocytes/Leukocytes (%) &gt;ULN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Monocytes/Leukocytes (%) &gt;ULN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="0" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="1" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="0" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="0" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Platelets (10^9/L) &gt;ULN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Platelets (10^9/L) &gt;ULN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="1" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="0" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="1" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="0" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="0" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="1" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in LDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
        <time_frame>Up to 22 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Full analysis set, comprised of patient who received at least one dose of study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in LDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
          <units>% change from baseline LDL-C</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.0" lower_limit="-32.1" upper_limit="-8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.6" lower_limit="-28.4" upper_limit="-7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.7" lower_limit="-25.2" upper_limit="-2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.1" lower_limit="-23.8" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.3" lower_limit="-33.7" upper_limit="-6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.5" lower_limit="-33.6" upper_limit="-4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" lower_limit="-28.2" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
        <time_frame>Up to 22 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Full analysis set, comprised of patient who received at least one dose of study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
          <units>% change from baseline HDL-C</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" lower_limit="1.3" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="6.2" upper_limit="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="-8.4" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="-10.8" upper_limit="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="-12.7" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="-9.4" upper_limit="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="-13.1" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Cholesterol (TC) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
        <time_frame>Up to 22 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Full analysis set, comprised of patient who received at least one dose of study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Cholesterol (TC) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
          <units>% change from baseline TC</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.4" lower_limit="-29.7" upper_limit="-7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.8" lower_limit="-25.7" upper_limit="-6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.0" lower_limit="-23.6" upper_limit="-3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" lower_limit="-22.3" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.9" lower_limit="-31.1" upper_limit="-6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.3" lower_limit="-30.2" upper_limit="-4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" lower_limit="-26.3" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Triglycerides (TG) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
        <time_frame>Up to 22 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Full analysis set, comprised of patient who received at least one dose of study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Triglycerides (TG) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
          <units>% change from baseline TG</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.3" lower_limit="-31.9" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.4" lower_limit="-34.2" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.2" lower_limit="-36.1" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.0" lower_limit="-42.8" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.3" lower_limit="-45.0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.7" lower_limit="-43.4" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.5" lower_limit="-47.0" upper_limit="-3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Non-HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
        <time_frame>Up to 22 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Full analysis set, comprised of patient who received at least one dose of study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Non-HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
          <units>% change from baseline Non-HDL-C</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.7" lower_limit="-32.7" upper_limit="-9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.2" lower_limit="-28.8" upper_limit="-8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.7" lower_limit="-25.7" upper_limit="-4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" lower_limit="-24.3" upper_limit="-0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.1" lower_limit="-33.8" upper_limit="-8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.0" lower_limit="-33.2" upper_limit="-6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.2" lower_limit="-28.1" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in LDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
        <time_frame>Up to 22 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Full analysis set, comprised of patient who received at least one dose of study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in LDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
          <units>% change from baseline LDL-C/HDL-C</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.4" lower_limit="-51.6" upper_limit="-24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.2" lower_limit="-52.8" upper_limit="-26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.1" lower_limit="-48.8" upper_limit="-20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.0" lower_limit="-49.5" upper_limit="-16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.6" lower_limit="-61.3" upper_limit="-31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.2" lower_limit="-57.2" upper_limit="-21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.8" lower_limit="-47.4" upper_limit="-0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in TC/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
        <time_frame>Up to 22 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Full analysis set, comprised of patient who received at least one dose of study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in TC/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
          <units>% change from baseline TC/HDL-C</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.6" lower_limit="-38.3" upper_limit="-21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.4" lower_limit="-38.5" upper_limit="-18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.5" lower_limit="-32.0" upper_limit="-7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.6" lower_limit="-30.7" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.1" lower_limit="-38.6" upper_limit="-6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.2" lower_limit="-43.2" upper_limit="-11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.6" lower_limit="-33.7" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Non-HDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
        <time_frame>Up to 22 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Full analysis set, comprised of patient who received at least one dose of study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Non-HDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
          <units>% change from baseline Non-HDL-C/HDL-C</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.9" lower_limit="-41.2" upper_limit="-23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.5" lower_limit="-41.2" upper_limit="-20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.3" lower_limit="-34.3" upper_limit="-8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.1" lower_limit="-32.8" upper_limit="-0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.3" lower_limit="-41.3" upper_limit="-7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.8" lower_limit="-46.0" upper_limit="-13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.6" lower_limit="-36.2" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in ApoB From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
        <time_frame>Up to 22 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Full analysis set, comprised of patient who received at least one dose of study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in ApoB From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
          <units>% change from baseline ApoB</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.5" lower_limit="-29.8" upper_limit="-9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.7" lower_limit="-26.7" upper_limit="-9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.2" lower_limit="-23.9" upper_limit="-5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" lower_limit="-20.4" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.2" lower_limit="-27.9" upper_limit="-4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.2" lower_limit="-30.2" upper_limit="-6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.5" lower_limit="-23.5" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
        <time_frame>Up to 22 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Full analysis set, comprised of patient who received at least one dose of study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
          <units>% change from baseline ApoA-1</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="0.0" upper_limit="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="-2.3" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="-4.9" upper_limit="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="-5.3" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-11.5" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="-2.6" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="-12.9" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in ApoB/ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
        <time_frame>Up to 22 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Full analysis set, comprised of patient who received at least one dose of study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in ApoB/ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis</title>
          <units>% change from baseline ApoB/ApoA-1</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.3" lower_limit="-34.3" upper_limit="-10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.1" lower_limit="-32.7" upper_limit="-9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.9" lower_limit="-31.2" upper_limit="-4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.7" lower_limit="-30.2" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.0" lower_limit="-33.1" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.0" lower_limit="-41.1" upper_limit="-7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.7" lower_limit="-33.7" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Profile in Terms of Trough Concentrations in Pediatric HoFH Taking a Daily Dose of Rosuvastatin 40mg</title>
        <time_frame>Up to 22 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full Analysis Set</title>
            <description>Full analysis set, comprised of patient who received at least one dose of study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Profile in Terms of Trough Concentrations in Pediatric HoFH Taking a Daily Dose of Rosuvastatin 40mg</title>
          <units>ng/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 292</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 376</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Blood Urea Nitrogen (mg/dL) &lt;LLN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Blood Urea Nitrogen (mg/dL) &lt;LLN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.56"/>
                    <measurement group_id="O2" value="0" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="1" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.25"/>
                    <measurement group_id="O2" value="0" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="0" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Chloride (mmol/L) &gt;ULN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Chloride (mmol/L) &gt;ULN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="1" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="1" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="1" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="1" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="0" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="1" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="1" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Creatine Kinase (U/L) &gt;ULN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Creatine Kinase (U/L) &gt;ULN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="0" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.15"/>
                    <measurement group_id="O2" value="0" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="0" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="0" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Glucose (mg/dL) &gt;ULN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Glucose (mg/dL) &gt;ULN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="1" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="0" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="0" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="0" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="1" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lactate Dehydrogenase (U/L) &lt;LLN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lactate Dehydrogenase (U/L) &lt;LLN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="0" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="0" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="0" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="1" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Phosphate (mg/dL) &gt;ULN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Phosphate (mg/dL) &gt;ULN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="1" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="0" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="0" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="1" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="1" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Protein (g/dL) &gt;ULN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Protein (g/dL) &gt;ULN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="1" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="0" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="1" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.15"/>
                    <measurement group_id="O2" value="0" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="0" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="0" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Sodium (mmol/L) &lt;LLN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Sodium (mmol/L) &lt;LLN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="23.56"/>
                    <measurement group_id="O2" value="1" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="1" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="0" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="1" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="1" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Urate (mg/dL) &gt;ULN</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Urate (mg/dL) &gt;ULN</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.57"/>
                    <measurement group_id="O2" value="1" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.56"/>
                    <measurement group_id="O2" value="1" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.02"/>
                    <measurement group_id="O2" value="1" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.15"/>
                    <measurement group_id="O2" value="1" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.25"/>
                    <measurement group_id="O2" value="1" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="19.47"/>
                    <measurement group_id="O2" value="1" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="20.22"/>
                    <measurement group_id="O2" value="1" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="20.43"/>
                    <measurement group_id="O2" value="1" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Ketones</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Ketones</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="1" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="0" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="1" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="0" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Occult Blood</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Occult Blood</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.57"/>
                    <measurement group_id="O2" value="1" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="23.57"/>
                    <measurement group_id="O2" value="1" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.90"/>
                    <measurement group_id="O2" value="2" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.56"/>
                    <measurement group_id="O2" value="1" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.02"/>
                    <measurement group_id="O2" value="1" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.15"/>
                    <measurement group_id="O2" value="1" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.25"/>
                    <measurement group_id="O2" value="1" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="19.47"/>
                    <measurement group_id="O2" value="1" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="20.22"/>
                    <measurement group_id="O2" value="1" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="20.43"/>
                    <measurement group_id="O2" value="1" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Protein</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Protein</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="23.57"/>
                    <measurement group_id="O2" value="1" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.57"/>
                    <measurement group_id="O2" value="1" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="23.90"/>
                    <measurement group_id="O2" value="1" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.56"/>
                    <measurement group_id="O2" value="0" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="24.02"/>
                    <measurement group_id="O2" value="1" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="24.15"/>
                    <measurement group_id="O2" value="0" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.25"/>
                    <measurement group_id="O2" value="1" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="19.47"/>
                    <measurement group_id="O2" value="1" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="20.22"/>
                    <measurement group_id="O2" value="1" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="20.43"/>
                    <measurement group_id="O2" value="1" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal ECG, Abnormalities</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal ECG, Abnormalities</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Physical Exams, Cardiovascular</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Physical Exams, Cardiovascular</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="0" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="1" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="1" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="1" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="1" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Physical Exams, General Appearance</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Physical Exams, General Appearance</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.57"/>
                    <measurement group_id="O2" value="2" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.57"/>
                    <measurement group_id="O2" value="2" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.90"/>
                    <measurement group_id="O2" value="2" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.56"/>
                    <measurement group_id="O2" value="2" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.02"/>
                    <measurement group_id="O2" value="2" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.15"/>
                    <measurement group_id="O2" value="2" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.25"/>
                    <measurement group_id="O2" value="2" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="19.47"/>
                    <measurement group_id="O2" value="2" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="20.22"/>
                    <measurement group_id="O2" value="2" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="20.43"/>
                    <measurement group_id="O2" value="2" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Physical Exams, Head and Neck</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Physical Exams, Head and Neck</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="1" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="1" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="1" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="1" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="1" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="1" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="1" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="1" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="1" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Physical Exams, Musculoskeletal/Extremities</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Physical Exams, Musculoskeletal/Extremities</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="0" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="0" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="1" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="0" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Physical Exams, Skin</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Physical Exams, Skin</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="23.57"/>
                    <measurement group_id="O2" value="2" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="23.57"/>
                    <measurement group_id="O2" value="2" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="23.90"/>
                    <measurement group_id="O2" value="2" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="23.56"/>
                    <measurement group_id="O2" value="2" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="24.02"/>
                    <measurement group_id="O2" value="2" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="24.15"/>
                    <measurement group_id="O2" value="2" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="24.25"/>
                    <measurement group_id="O2" value="2" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="19.47"/>
                    <measurement group_id="O2" value="2" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="20.22"/>
                    <measurement group_id="O2" value="2" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="20.43"/>
                    <measurement group_id="O2" value="1" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="25.46"/>
                    <measurement group_id="O2" value="1" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability in Terms of Abnormal Vital Signs</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequence A</title>
            <description>Rosuva/Placebo in the D3561C00004 cross-over phase</description>
          </group>
          <group group_id="O2">
            <title>Sequence B</title>
            <description>Placebo/Rosuva in the D3561C00004 cross-over phase</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability in Terms of Abnormal Vital Signs</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.57"/>
                    <measurement group_id="O2" value="0" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.90"/>
                    <measurement group_id="O2" value="0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="23.56"/>
                    <measurement group_id="O2" value="0" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.02"/>
                    <measurement group_id="O2" value="0" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.15"/>
                    <measurement group_id="O2" value="0" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="24.25"/>
                    <measurement group_id="O2" value="0" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="19.47"/>
                    <measurement group_id="O2" value="0" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.22"/>
                    <measurement group_id="O2" value="0" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="20.43"/>
                    <measurement group_id="O2" value="0" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.46"/>
                    <measurement group_id="O2" value="0" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>72 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Overall</title>
          <description>All patients</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Attention deficit/hyperactivity disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Upon completion of the Clinical Trial (CT), the Principal Investigator (PI) may prepare the data derived from the CT for publication or presentation. Material should be submitted to the Sponsor for review prior to review or submission for publication. Publications from individual sites must not precede the primary manuscript, but if published within twelve months after completion of the CT, the PI has the right to publish or present the methods and results of the CT.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robin Mukherjee</name_or_title>
      <organization>AstraZeneca Plc</organization>
      <phone>+46317761000</phone>
      <email>robin.mukherjee@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

